156 Renal Cell Carcinoma Multimodality Conference: (030623)

Dallas, TX US
March 6, 2023

To improve the care of patients with RCC. This Conference is focused primarily on the discussion of patient cases and periodically of clinical and basic research relevant to RCC

Target Audience

For physicians, PAs, RNs, researchers, medical and graduate students

Learning Objectives

The advancement of diagnosis and treatment of RCC through interdisciplinary expert discussions.  After this conference, participants can explain and utilize  information obtained for enhanced patient care

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
03/06/2023
Course expires: 
03/06/2023
Event starts: 
03/06/2023 - 5:15pm CST
Event ends: 
03/06/2023 - 6:15pm CST
Cost:
$0.00
Part of: 
156 RENAL CELL CARCINOMA MULTIMODALITY CONFERENCE 2023
Add to calendar: 
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75235
United States

 

 

 

 

 

 

 

Committee member(s)

James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.

Jeffrey Cadeddu, MD

has a financial relationship (Stock) with Onconano;.
has a financial relationship (Stock Options) with Levita Magnetics;.
has a financial relationship (Professional Services) with DeepQure;.
has a financial relationship (Professional Services) with Distalmotion;.

Hans Hammers, MD PhD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Independent contractor) with Corvus;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Armo Biosciences;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Surface Oncology;.

Raquibul Hannan, MD, PhD, Associate Professor

has no relevant financial relationships to disclose at this time.
Course Director(s)

James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
Moderator(s)

Payal Kapur, MD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Waddah Arafat

has a financial relationship (Professional Services) with DAVA Oncology;.
has a financial relationship (Professional Services) with Seagen;.

James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.

Suzanne Cole, MD

has no relevant financial relationships to disclose at this time.

Kevin Courtney, MD, PhD

has a financial relationship (Patent) with Athena Diagnostics;.
has a financial relationship (Stock) with Regeneron Pharmaceuticals Inc;.
has a financial relationship (Grant Or Contract) with Astellas;.

Payal Kapur, MD

has no relevant financial relationships to disclose at this time.

Ivan Pedrosa, M.D., Ph.D.

has a financial relationship (Stock Options) with Health Tech International;.

Qian Qin, MD

has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with MJH;.

Jacob Taylor, MD MPH

has no relevant financial relationships to disclose at this time.

Mitch von Itzstein, MD

has no relevant financial relationships to disclose at this time.

Tian Zhang, MD, MHS

has a financial relationship (Grant Or Contract) with Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas, Eli Lilly, Tempus;.
has a financial relationship (Independent contractor) with Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly;.
has a financial relationship (Independent contractor) with Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.